Vamorolone | FAMHP

Active substance	17α,21‐dihydroxy‐16α‐methyl‐pregna‐1,4,9(11)‐triene‐3,20‐dione
Holder	Santhera Pharmaceuticals (Switzerland)
Status	closed
Indication	Duchenne Muscular Dystrophy in boys who are completing the VBP15-004 trial
Public documents	Approbation
	Approbation amendment 1 Approbation amendment_2 Approbation amendment 3
	Information for the patient
	Information for the patient amendment 1 Information for the patient amendment_2 Information for the patient amendment 3
	Informed consent
	Informed consent amendment 1 Informed consent amendment_2 Informed consent amendment 3
Last update	21/03/2025